MariMed Future Growth
Future criteria checks 0/6
MariMed is forecast to grow revenue at 8.1% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 23.7% |
| Revenue growth rate | 8.1% |
| Future return on equity | 11.1% |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 188 | N/A | 10 | 14 | 1 |
| 12/31/2025 | 179 | N/A | 3 | 6 | 1 |
| 12/31/2024 | 161 | N/A | -6 | 8 | 1 |
| 9/30/2024 | 158 | -14 | -6 | 10 | N/A |
| 6/30/2024 | 156 | -17 | -2 | 18 | N/A |
| 3/31/2024 | 152 | -17 | -5 | 16 | N/A |
| 12/31/2023 | 149 | -16 | -12 | 8 | N/A |
| 9/30/2023 | 146 | -1 | -10 | 6 | N/A |
| 6/30/2023 | 141 | 6 | -11 | 2 | N/A |
| 3/31/2023 | 137 | 9 | -17 | -6 | N/A |
| 12/31/2022 | 134 | 13 | -5 | 7 | N/A |
| 9/30/2022 | 129 | 2 | 0 | 13 | N/A |
| 6/30/2022 | 129 | 2 | 3 | 20 | N/A |
| 3/31/2022 | 128 | 7 | 18 | 38 | N/A |
| 12/31/2021 | 121 | 7 | 18 | 36 | N/A |
| 9/30/2021 | 111 | 18 | 15 | 30 | N/A |
| 6/30/2021 | 91 | 17 | 10 | 20 | N/A |
| 3/31/2021 | 68 | 9 | 5 | 11 | N/A |
| 12/31/2020 | 51 | 2 | -1 | 3 | N/A |
| 9/30/2020 | 36 | -80 | -5 | 2 | N/A |
| 6/30/2020 | 33 | -89 | -10 | -2 | N/A |
| 3/31/2020 | 50 | -84 | -28 | -18 | N/A |
| 12/31/2019 | 46 | -81 | -34 | -24 | N/A |
| 9/30/2019 | 44 | -10 | -34 | -26 | N/A |
| 6/30/2019 | 36 | -7 | -32 | -25 | N/A |
| 3/31/2019 | 13 | -12 | -17 | -8 | N/A |
| 12/31/2018 | 12 | -14 | -12 | -3 | N/A |
| 9/30/2018 | 10 | -7 | -19 | -2 | N/A |
| 6/30/2018 | 8 | -4 | N/A | 2 | N/A |
| 3/31/2018 | 7 | -3 | N/A | 1 | N/A |
| 12/31/2017 | 6 | -1 | N/A | 2 | N/A |
| 9/30/2017 | 6 | 0 | N/A | 3 | N/A |
| 6/30/2017 | 5 | 0 | N/A | 0 | N/A |
| 3/31/2017 | 4 | 0 | N/A | 0 | N/A |
| 12/31/2016 | 4 | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MRMD's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if MRMD's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if MRMD's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MRMD's revenue (8.1% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: MRMD's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRMD's Return on Equity is forecast to be low in 3 years time (11.1%).